Promising treatment biomarkers in asthma

Barbara Bonnesen; Jens-Ulrik S Jensen; Alexander G Mathioudakis; Alexandru Corlateanu; Pradeesh Sivapalan

doi:10.3389/fdsfr.2023.1291471

Promising treatment biomarkers in asthma

Front Drug Saf Regul. 2023 Nov 7:3:1291471. doi: 10.3389/fdsfr.2023.1291471. eCollection 2023.

Authors

Barbara Bonnesen¹, Jens-Ulrik S Jensen^{1

2}, Alexander G Mathioudakis^{3

4}, Alexandru Corlateanu⁵, Pradeesh Sivapalan^{1

2}

Affiliations

¹ Department of Medicine, Section of Respiratory Medicine, Herlev-Gentofte Hospital, Hellerup, Denmark.
² Department of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark.
³ Division of Immunology, Immunity to Infection and Respiratory Medicine, School of Biological Sciences, The University of Manchester, Manchester, United Kingdom.
⁴ North West Lung Centre, Wythenshawe Hospital, Manchester University NHS Foundation Trust, Manchester Academic Health Science Centre, Manchester, United Kingdom.
⁵ Department of Respiratory Medicine, Nicolae Testemiţanu State University of Medicine and Pharmacy, Chisinau, Moldova.

Abstract

Asthma is a highly heterogenous disease which researchers over time have attempted to classify into different phenotypes and endotypes to improve diagnosis, prognosis and treatment. Earlier classifications based on reaction to environmental allergens, age, sex and lung function have evolved, and today, the use of precision medicine guided by biomarkers offers new perspectives on asthma management. Identifying biomarkers that may reveal the underlying pathophysiology of the disease will help to select the patients who will benefit most from specific treatments. This review explores the classification of asthma phenotypes and focuses on the most recent advances in using biomarkers to guide treatment.

Keywords: asthma; asthma treatment; biomarker; personalized medicine; phenotype.

Publication types

Review